Skip to content

Resistance Exercise in Rheumatic Disease

Resistance Exercise in Rheumatic Disease

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01599260
Enrollment
15
Registered
2012-05-15
Start date
2012-05-31
Completion date
2018-12-31
Last updated
2019-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis, Systemic Vasculitis

Brief summary

People with rheumatic disease often have decreased strength, muscle mass, and bone mineral density due to repeated bouts of inflammation, normal effects of aging, disuse, and inactivity. The medications used to quell the disease process, such as prednisone, can also have detrimental effects on body composition, strength, and functional capacity. The investigators propose to investigate the feasibility, safety, and effects of resistance exercise in older patients with rheumatoid arthritis (RA) and vasculitis. The unique resistance protocol the investigators propose involves performing movements in a slow and controlled fashion (i.e., no acceleration or use of momentum in the lifting and lowering of the resistance) to minimize force on the joints and connective tissues. This will be conducted in an individually-supervised environment with a new generation of exercise equipment that will accommodate their musculoskeletal capabilities and allow for reproducibility of the exercise protocol. The investigators intend to investigate the feasibility, safety, musculoskeletal, and psychological effects of this resistance exercise protocol in older patients with rheumatoid arthritis and vasculitis by testing their strength, body composition, functional ability, mood, and quality of life before and after this 16-week resistance exercise intervention.

Interventions

OTHERResistance Exercise

Two 30-minute individually supervised exercise sessions per week for 16-weeks

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of rheumatoid arthritis OR systemic vasculitis (defined as granulomatosis with polyangiitis, Churg-Strauss, microscopic polyangiitis, Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, or giant cell arteritis)

Exclusion criteria

* Non-English speaking * Pregnancy * Absolute cardiac or pulmonary contraindication to exercise * pacemaker

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with rheumatoid arthritis flares during the studyup to 16 weeksParticipants will be provided with questionnaires. They will be asked to report the number of arthritis flares since the last visit. Arthritis flares consist of pain and swelling of the joints. The total number of flares during the 16 week study will be reported.
Number of participants with reported physical injuries during the studyup to 16 weeksParticipants will be provided with questionnaires. They will be asked to report the number of injuries associated with the last visit (e.g. strains, sprains, and pulled muscles). The total number of injuries during the 16 week study will be reported.

Secondary

MeasureTime frameDescription
Change in Body composition after 16 weeks of resistance exercise16 weeksTo assess change in body composition associated with this resistance exercise protocol (after 16 weeks).
Change in Strength after 16 weeks of resistance exercise16 weeksWe will test if strength increases before and after the exercise intervention
Change in Functional status after 16 weeks of resistance exercise16 weeksWe will determine if functional status, as measured by the short physical performance battery, improves after 16 weeks
Change in inflammatory cytokine Interleukin-6 (IL6) after 16 weeks of resistance exercise16 weeksParticipants will have blood drawn before and after 16 weeks of exercise to determine if changes have occurred in their inflammatory cytokine.
Change in inflammatory cytokine C-reactive protein (CRP) after 16 weeks of resistance exercise16 weeksParticipants will have blood drawn before and after 16 weeks of exercise to determine if changes have occurred in their inflammatory cytokine.
Change in Erythrocyte Sedimentation Rate (ESR) after 16 weeks of resistance exercise16 weeksParticipants will have blood drawn before and after 16 weeks of exercise to determine if changes have occurred in their ESR

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026